Nectar builds a comprehensive, vertically integrated allergy healthcare platform leveraging data and clinical research.
Nectar has raised $16.5M in total funding. The most recent round was Series A. The last funding was announced in December 2022.
Nectar's investors include Obvious Ventures, Harmony Partners, Juxtapose.
Nectar is headquartered in New York, United States.
Nectar builds a comprehensive, vertically integrated allergy healthcare platform leveraging data and clinical research.
Nectar is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nectar — Funding & Investors." VCBacked, December 20, 2022, https://www.vcbacked.co/company/nectar-new-york. Accessed October 21, 2026.
VCBacked. (2022). Nectar — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/nectar-new-york
{{cite web |title=Nectar — Funding & Investors |url=https://www.vcbacked.co/company/nectar-new-york |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated